Drug Pipeline

Irinotecan Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
114
Active Studies
62
Recruiting
36
Phase 3
10
Top Sponsors
30
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT07328425
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round…
Trial sites expanded: 1 -> 5 locations
2026-06-11 NCT05083481
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab…
Trial terminated
2026-06-11 NCT05083481
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab…
date change Primary completion moved earlier: 2026-06-30 -> 2026-05-11
2026-06-11 NCT05083481
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab…
date change Completion moved earlier: 2026-06-30 -> 2026-05-11
2026-06-10 NCT07490301
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With…
Recruitment opened
2026-06-10 NCT07490301
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With…
Trial sites expanded: 0 -> 9 locations
2026-06-06 NCT06750094
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in…
Trial sites expanded: 241 -> 247 locations
2026-06-05 NCT05669339
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
date change Primary completion pushed: 2026-04 -> 2027-04
2026-06-05 NCT05669339
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
date change Completion pushed: 2026-04 -> 2027-04
2026-06-05 NCT07518147
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in…
Recruitment opened
2026-06-04 NCT04753879
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic…
date change Primary completion moved earlier: 2026-12-01 -> 2026-07-01
2026-06-04 NCT04753879
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic…
date change Completion moved earlier: 2029-12-01 -> 2026-07-01
2026-05-28 NCT06459180
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-28 NCT06346392
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-28 NCT06346392
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or…
Trial sites reduced: 186 -> 158 locations
2026-05-28 NCT06346392
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or…
date change Primary completion pushed: 2026-05-14 -> 2026-06-15
2026-05-28 NCT06346392
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or…
date change Completion pushed: 2026-09-14 -> 2026-10-14
2026-05-27 NCT06607185
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Trial sites reduced: 56 -> 47 locations
2026-05-23 NCT05239741
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-23 NCT03715933
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors…
Enrollment increased: 321 -> 411 participants
Showing 20 of 30 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-02 NCT07619313 AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients… Phase 1 Not Yet Recruiting
2026-06-02 NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… Phase 3 Recruiting
2026-05-26 NCT07606599 A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With… Phase 3 Not Yet Recruiting
Active Studies by Phase
Phase 4
1
Phase 3
34
Phase 2/3
2
Phase 2
35
Phase 1/2
18
Phase 1
22
Early Phase 1
1
Not specified
1
Active Trials — top 25 of 114
NCT IDTitleConditionStatus
Phase 4
NCT07094893 Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type… Colorectal Cancer Not Yet Recruiting
Phase 3
NCT06644781 A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic… Esophageal Squamous Cell Carcinoma Recruiting
NCT04342910 Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With… Gastric Cancer Recruiting
NCT07284134 JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced… Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting
NCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer Colorectal Adenocarcinoma Recruiting
NCT06958328 Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Recruiting
NCT06401330 A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology… Stage I Mixed Cell Type Kidney Wilms Tumor Recruiting
NCT05677490 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced… Advanced Esophageal Adenocarcinoma Recruiting
NCT06998940 Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or… Locally Advanced Pancreatic Adenocarcinoma Recruiting
NCT05863195 Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of… Metastatic Colorectal Carcinoma Recruiting
NCT07409272 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either… Pancreatic Cancer Recruiting
NCT07621718 Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of… Pancreatic Cancer Recruiting
NCT07518147 A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in… Gastric Cancer Recruiting
NCT03303495 A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC Colorectal Neoplasms Recruiting
NCT06662786 A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI… Colorectal Neoplasms Recruiting
NCT06750094 A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in… Colorectal Neoplasms Recruiting
NCT06172296 Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of… Ganglioneuroblastoma, Nodular Recruiting
NCT06351020 LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and… Locally Advanced or Metastatic GC and GCJ Adenocarcinoma Active, Not Recruiting
NCT04340141 Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable… Pancreatic Adenosquamous Carcinoma Active, Not Recruiting
NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic… Gastroesophageal Cancer Active, Not Recruiting
NCT04094688 Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or… Colorectal Adenocarcinoma Active, Not Recruiting
NCT07466316 A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose… Rhabdomyosarcoma Not Yet Recruiting
NCT07487896 A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With… Advanced Esophageal Squamous Cell Carcinoma Not Yet Recruiting
NCT06304974 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With… Esophageal Squamous Cell Carcinoma Active, Not Recruiting
NCT00980460 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer PRETEXT I Hepatoblastoma Active, Not Recruiting
Sponsors Running Irinotecan Trials
Disease Areas
Get alerts when Irinotecan trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free